25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

IMU (Imugene) Stock Analysis
Buy, Hold or Sell?

Let's analyze Imugene together

I guess you are interested in Imugene Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Imugene’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Imugene’s Price Targets

I'm going to help you getting a better view of Imugene Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Imugene Ltd

I send you an email if I find something interesting about Imugene Ltd.

1. Quick Overview

1.1. Quick analysis of Imugene (30 sec.)










1.2. What can you expect buying and holding a share of Imugene? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
A$0.40
Expected worth in 1 year
A$1.89
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$1.49
Return On Investment
488.9%

For what price can you sell your share?

Current Price per Share
A$0.31
Expected price per share
A$0.31 - A$0.476
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Imugene (5 min.)




Live pricePrice per Share (EOD)
A$0.31
Intrinsic Value Per Share
A$-4.87 - A$-2.09
Total Value Per Share
A$-4.46 - A$-1.69

2.2. Growth of Imugene (5 min.)




Is Imugene growing?

Current yearPrevious yearGrowGrow %
How rich?$78.7m$126.2m-$47.5m-60.4%

How much money is Imugene making?

Current yearPrevious yearGrowGrow %
Making money-$99.6m-$25.2m-$74.3m-74.7%
Net Profit Margin-1,384.7%-321.9%--

How much money comes from the company's main activities?

2.3. Financial Health of Imugene (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#355 / 853

Most Revenue
#309 / 853

Most Profit
#821 / 853

Most Efficient
#688 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Imugene?

Welcome investor! Imugene's management wants to use your money to grow the business. In return you get a share of Imugene.

First you should know what it really means to hold a share of Imugene. And how you can make/lose money.

Speculation

The Price per Share of Imugene is A$0.305. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Imugene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Imugene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.40. Based on the TTM, the Book Value Change Per Share is A$0.37 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.44 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Imugene.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.34-111.3%-0.34-111.3%0.00-1.3%-0.14-46.9%-0.09-31.0%-0.05-15.7%
Usd Book Value Change Per Share0.2581.4%0.2581.4%-0.29-96.6%0.0413.2%0.0517.3%0.038.6%
Usd Dividend Per Share0.000.0%0.000.0%0.012.7%0.012.4%0.014.3%0.012.2%
Usd Total Gains Per Share0.2581.4%0.2581.4%-0.29-93.9%0.0515.6%0.0721.6%0.0310.7%
Usd Price Per Share0.04-0.04-0.06-0.07-0.10-0.05-
Price to Earnings Ratio-0.11--0.11--15.06--5.52--6.85--8.18-
Price-to-Total Gains Ratio0.15-0.15--0.21-0.20-0.89-3.66-
Price to Book Ratio0.14-0.14-3.01-1.18-1.45-1.99-
Price-to-Total Gains Ratio0.15-0.15--0.21-0.20-0.89-3.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.203008
Number of shares4925
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.250.05
Usd Total Gains Per Share0.250.07
Gains per Quarter (4925 shares)1,222.04324.22
Gains per Year (4925 shares)4,888.161,296.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104888487826010371287
209776976652020742584
30146641465478031113881
401955319542104041485178
502444124430130051846475
602932929318156062217772
703421734206182072589069
8039105390942080829510366
9043993439822340933211663
100488824887026001036912960

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%4.028.00.012.5%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%6.04.00.060.0%15.017.00.046.9%
Dividend per Share0.00.01.00.0%2.00.01.066.7%4.00.01.080.0%4.00.06.040.0%4.00.028.012.5%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%6.04.00.060.0%15.017.00.046.9%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Imugene Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3730.3730%-0.442+219%0.060+516%0.079+371%0.039+848%
Book Value Per Share--0.4030.4030%0.030+1234%0.302+33%0.228+76%0.117+243%
Current Ratio--3.8583.8580%27.229-86%15.470-75%13.291-71%12.944-70%
Debt To Asset Ratio--0.2190.2190%0.038+480%0.106+107%0.099+121%0.112+95%
Debt To Equity Ratio--0.2800.2800%0.039+615%0.128+119%0.116+142%0.130+115%
Dividend Per Share----0%0.012-100%0.011-100%0.020-100%0.010-100%
Enterprise Value--78124922.91278124922.9120%716800215.057-89%312909779.616-75%243324515.906-68%142887344.063-45%
Eps---0.510-0.5100%-0.006-99%-0.215-58%-0.142-72%-0.072-86%
Ev To Ebitda Ratio---0.528-0.5280%-15.114+2763%-6.211+1077%-6.872+1202%-13.880+2529%
Ev To Sales Ratio--7.2277.2270%60.859-88%26.391-73%26.650-73%25.172-71%
Free Cash Flow Per Share---0.364-0.3640%-0.005-99%-0.158-57%-0.108-70%-0.055-85%
Free Cash Flow To Equity Per Share---0.195-0.1950%0.008-2405%0.018-1205%0.011-1917%0.006-3357%
Gross Profit Margin--1.0781.0780%1.013+6%1.033+4%1.023+5%1.072+1%
Intrinsic Value_10Y_max---2.089----------
Intrinsic Value_10Y_min---4.866----------
Intrinsic Value_1Y_max---0.088----------
Intrinsic Value_1Y_min---0.244----------
Intrinsic Value_3Y_max---0.358----------
Intrinsic Value_3Y_min---0.948----------
Intrinsic Value_5Y_max---0.739----------
Intrinsic Value_5Y_min---1.883----------
Market Cap89496154.880+81%16725510.91216725510.9120%571086482.057-97%213543131.950-92%174223753.106-90%105741423.063-84%
Net Profit Margin---13.847-13.8470%-3.219-77%-6.662-52%-5.016-64%-3.682-73%
Operating Margin---14.229-14.2290%-4.214-70%-7.445-48%-5.885-59%-4.414-69%
Operating Ratio--15.22015.2200%4.355+249%7.827+94%6.126+148%4.718+223%
Pb Ratio0.757+81%0.1410.1410%3.012-95%1.178-88%1.450-90%1.985-93%
Pe Ratio-0.598-435%-0.112-0.1120%-15.062+13380%-5.523+4843%-6.847+6027%-8.179+7219%
Price Per Share0.305+81%0.0570.0570%0.091-37%0.109-48%0.143-60%0.079-28%
Price To Free Cash Flow Ratio-0.838-435%-0.157-0.1570%-19.178+12143%-7.014+4378%-7.504+4691%-8.107+5075%
Price To Total Gains Ratio0.818+81%0.1530.1530%-0.212+238%0.201-24%0.894-83%3.655-96%
Quick Ratio--3.7073.7070%27.163-86%15.348-76%13.197-72%12.719-71%
Return On Assets---0.989-0.9890%-0.192-81%-0.479-52%-0.371-62%-0.309-69%
Return On Equity---1.266-1.2660%-0.200-84%-0.580-54%-0.440-65%-0.362-71%
Total Gains Per Share--0.3730.3730%-0.430+215%0.071+422%0.099+277%0.049+657%
Usd Book Value--78710133.29978710133.2990%126215066.931-38%99082359.279-21%76066000.957+3%42675784.653+84%
Usd Book Value Change Per Share--0.2480.2480%-0.295+219%0.040+516%0.053+371%0.026+848%
Usd Book Value Per Share--0.2680.2680%0.020+1234%0.201+33%0.152+76%0.078+243%
Usd Dividend Per Share----0%0.008-100%0.007-100%0.013-100%0.007-100%
Usd Enterprise Value--51999948.69051999948.6900%477102223.142-89%208272749.313-75%161956797.787-68%95105816.209-45%
Usd Eps---0.340-0.3400%-0.004-99%-0.143-58%-0.095-72%-0.048-86%
Usd Free Cash Flow---71071388.211-71071388.2110%-19820709.376-72%-37158865.425-48%-26314968.044-63%-14540944.205-80%
Usd Free Cash Flow Per Share---0.242-0.2420%-0.003-99%-0.105-57%-0.072-70%-0.037-85%
Usd Free Cash Flow To Equity Per Share---0.130-0.1300%0.006-2405%0.012-1205%0.007-1917%0.004-3357%
Usd Market Cap59568640.688+81%11132500.06311132500.0630%380115162.457-97%142134308.626-92%115963330.067-90%70381491.191-84%
Usd Price Per Share0.203+81%0.0380.0380%0.061-37%0.073-48%0.095-60%0.053-28%
Usd Profit---99627673.600-99627673.6000%-25236224.000-75%-50023168.000-50%-33869455.360-66%-18225192.960-82%
Usd Revenue--7195136.0007195136.0000%7839436.800-8%7889134.933-9%6246522.880+15%3744577.475+92%
Usd Total Gains Per Share--0.2480.2480%-0.286+215%0.048+422%0.066+277%0.033+657%
 EOD+6 -2MRQTTM+0 -0YOY+11 -293Y+10 -305Y+12 -2810Y+12 -28

3.3 Fundamental Score

Let's check the fundamental score of Imugene Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.598
Price to Book Ratio (EOD)Between0-10.757
Net Profit Margin (MRQ)Greater than0-13.847
Operating Margin (MRQ)Greater than0-14.229
Quick Ratio (MRQ)Greater than13.707
Current Ratio (MRQ)Greater than13.858
Debt to Asset Ratio (MRQ)Less than10.219
Debt to Equity Ratio (MRQ)Less than10.280
Return on Equity (MRQ)Greater than0.15-1.266
Return on Assets (MRQ)Greater than0.05-0.989
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Imugene Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.745
Ma 20Greater thanMa 500.289
Ma 50Greater thanMa 1000.297
Ma 100Greater thanMa 2000.426
OpenGreater thanClose0.340
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.

Fundamental data was last updated by Penke on 2025-08-22 17:22:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Imugene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Imugene to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -1,384.7%Β means thatΒ $-13.85 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Imugene Ltd:

  • The MRQ is -1,384.7%. The company is making a huge loss. -2
  • The TTM is -1,384.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,384.7%TTM-1,384.7%0.0%
TTM-1,384.7%YOY-321.9%-1,062.7%
TTM-1,384.7%5Y-501.6%-883.1%
5Y-501.6%10Y-368.2%-133.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,384.7%-86.1%-1,298.6%
TTM-1,384.7%-169.5%-1,215.2%
YOY-321.9%-209.8%-112.1%
3Y-666.2%-284.5%-381.7%
5Y-501.6%-380.6%-121.0%
10Y-368.2%-519.5%+151.3%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Imugene is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Imugene to theΒ Biotechnology industry mean.
  • -98.9% Return on Assets means thatΒ Imugene generatedΒ $-0.99 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Imugene Ltd:

  • The MRQ is -98.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -98.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-98.9%TTM-98.9%0.0%
TTM-98.9%YOY-19.2%-79.6%
TTM-98.9%5Y-37.1%-61.8%
5Y-37.1%10Y-30.9%-6.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-98.9%-12.1%-86.8%
TTM-98.9%-12.0%-86.9%
YOY-19.2%-11.2%-8.0%
3Y-47.9%-12.0%-35.9%
5Y-37.1%-11.7%-25.4%
10Y-30.9%-13.8%-17.1%
4.3.1.3. Return on Equity

Shows how efficient Imugene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Imugene to theΒ Biotechnology industry mean.
  • -126.6% Return on Equity means Imugene generated $-1.27Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Imugene Ltd:

  • The MRQ is -126.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -126.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-126.6%TTM-126.6%0.0%
TTM-126.6%YOY-20.0%-106.6%
TTM-126.6%5Y-44.0%-82.6%
5Y-44.0%10Y-36.2%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-126.6%-14.3%-112.3%
TTM-126.6%-15.2%-111.4%
YOY-20.0%-15.2%-4.8%
3Y-58.0%-16.8%-41.2%
5Y-44.0%-17.5%-26.5%
10Y-36.2%-19.6%-16.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Imugene Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Imugene is operatingΒ .

  • Measures how much profit Imugene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Imugene to theΒ Biotechnology industry mean.
  • An Operating Margin of -1,422.9%Β means the company generated $-14.23 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Imugene Ltd:

  • The MRQ is -1,422.9%. The company is operating very inefficient. -2
  • The TTM is -1,422.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,422.9%TTM-1,422.9%0.0%
TTM-1,422.9%YOY-421.4%-1,001.6%
TTM-1,422.9%5Y-588.5%-834.4%
5Y-588.5%10Y-441.4%-147.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,422.9%-161.5%-1,261.4%
TTM-1,422.9%-286.7%-1,136.2%
YOY-421.4%-254.3%-167.1%
3Y-744.5%-270.1%-474.4%
5Y-588.5%-356.3%-232.2%
10Y-441.4%-528.7%+87.3%
4.3.2.2. Operating Ratio

Measures how efficient Imugene is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 15.22 means that the operating costs are $15.22 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Imugene Ltd:

  • The MRQ is 15.220. The company is inefficient in keeping operating costs low. -1
  • The TTM is 15.220. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ15.220TTM15.2200.000
TTM15.220YOY4.355+10.865
TTM15.2205Y6.126+9.094
5Y6.12610Y4.718+1.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.2201.929+13.291
TTM15.2202.934+12.286
YOY4.3552.982+1.373
3Y7.8273.799+4.028
5Y6.1264.893+1.233
10Y4.7186.841-2.123
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Imugene Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Imugene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 3.86Β means the company has $3.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Imugene Ltd:

  • The MRQ is 3.858. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.858. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.858TTM3.8580.000
TTM3.858YOY27.229-23.371
TTM3.8585Y13.291-9.433
5Y13.29110Y12.944+0.347
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8583.480+0.378
TTM3.8583.736+0.122
YOY27.2294.133+23.096
3Y15.4704.591+10.879
5Y13.2915.762+7.529
10Y12.9446.154+6.790
4.4.3.2. Quick Ratio

Measures if Imugene is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Imugene to theΒ Biotechnology industry mean.
  • A Quick Ratio of 3.71Β means the company can pay off $3.71 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Imugene Ltd:

  • The MRQ is 3.707. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.707. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.707TTM3.7070.000
TTM3.707YOY27.163-23.456
TTM3.7075Y13.197-9.490
5Y13.19710Y12.719+0.478
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7072.930+0.777
TTM3.7073.192+0.515
YOY27.1633.990+23.173
3Y15.3484.381+10.967
5Y13.1975.837+7.360
10Y12.7196.540+6.179
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Imugene Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ImugeneΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Imugene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22Β means that Imugene assets areΒ financed with 21.9% credit (debt) and the remaining percentage (100% - 21.9%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Imugene Ltd:

  • The MRQ is 0.219. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.219. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.219TTM0.2190.000
TTM0.219YOY0.038+0.181
TTM0.2195Y0.099+0.120
5Y0.09910Y0.112-0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2190.339-0.120
TTM0.2190.359-0.140
YOY0.0380.334-0.296
3Y0.1060.341-0.235
5Y0.0990.349-0.250
10Y0.1120.379-0.267
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Imugene is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Imugene to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 28.0% means that company has $0.28 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Imugene Ltd:

  • The MRQ is 0.280. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.280. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.280TTM0.2800.000
TTM0.280YOY0.039+0.241
TTM0.2805Y0.116+0.165
5Y0.11610Y0.130-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2800.391-0.111
TTM0.2800.432-0.152
YOY0.0390.427-0.388
3Y0.1280.462-0.334
5Y0.1160.459-0.343
10Y0.1300.514-0.384
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Imugene generates.

  • Above 15 is considered overpriced butΒ always compareΒ Imugene to theΒ Biotechnology industry mean.
  • A PE ratio of -0.11 means the investor is paying $-0.11Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Imugene Ltd:

  • The EOD is -0.598. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.112. Based on the earnings, the company is expensive. -2
  • The TTM is -0.112. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.598MRQ-0.112-0.486
MRQ-0.112TTM-0.1120.000
TTM-0.112YOY-15.062+14.951
TTM-0.1125Y-6.847+6.735
5Y-6.84710Y-8.179+1.332
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.598-2.542+1.944
MRQ-0.112-2.355+2.243
TTM-0.112-2.660+2.548
YOY-15.062-3.770-11.292
3Y-5.523-3.843-1.680
5Y-6.847-6.412-0.435
10Y-8.179-7.084-1.095
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Imugene Ltd:

  • The EOD is -0.838. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.157. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.157. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.838MRQ-0.157-0.682
MRQ-0.157TTM-0.1570.000
TTM-0.157YOY-19.178+19.021
TTM-0.1575Y-7.504+7.348
5Y-7.50410Y-8.107+0.602
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.838-3.327+2.489
MRQ-0.157-3.016+2.859
TTM-0.157-3.645+3.488
YOY-19.178-4.377-14.801
3Y-7.014-5.257-1.757
5Y-7.504-8.487+0.983
10Y-8.107-9.626+1.519
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Imugene is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.14 means the investor is paying $0.14Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Imugene Ltd:

  • The EOD is 0.757. Based on the equity, the company is cheap. +2
  • The MRQ is 0.141. Based on the equity, the company is cheap. +2
  • The TTM is 0.141. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.757MRQ0.141+0.615
MRQ0.141TTM0.1410.000
TTM0.141YOY3.012-2.870
TTM0.1415Y1.450-1.308
5Y1.45010Y1.985-0.535
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.7572.201-1.444
MRQ0.1412.007-1.866
TTM0.1412.189-2.048
YOY3.0122.409+0.603
3Y1.1782.558-1.380
5Y1.4503.764-2.314
10Y1.9854.462-2.477
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Imugene Ltd.

4.8.2. Funds holding Imugene Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-01-31DFA International Sustainability Core 1 Portfolio0.029999999-1293602--
Total 0.0299999990129360200.0%
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-06-302021-06-302022-06-302023-06-302024-06-30
Other Stockholders Equity  -45,48745,4870-127,268-127,268-45,698-172,966173,160194
Total Other Income Expense Net 297-2871161721,7801,852-15,217-13,365



5.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets151,398
Total Liabilities33,143
Total Stockholder Equity118,254
 As reported
Total Liabilities 33,143
Total Stockholder Equity+ 118,254
Total Assets = 151,398

Assets

Total Assets151,398
Total Current Assets113,034
Long-term Assets38,364
Total Current Assets
Cash And Cash Equivalents 93,108
Short-term Investments 1,435
Net Receivables 12,619
Other Current Assets 5,872
Total Current Assets  (as reported)113,034
Total Current Assets  (calculated)113,034
+/-0
Long-term Assets
Property Plant Equipment 1,699
Long Term Investments 2,413
Intangible Assets 34,120
Long-term Assets Other 133
Long-term Assets  (as reported)38,364
Long-term Assets  (calculated)38,364
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities29,299
Long-term Liabilities3,845
Total Stockholder Equity118,254
Total Current Liabilities
Short-term Debt 912
Accounts payable 5,968
Other Current Liabilities 22,418
Total Current Liabilities  (as reported)29,299
Total Current Liabilities  (calculated)29,299
+/-0
Long-term Liabilities
Long term Debt Total 634
Capital Lease Obligations Min Short Term Debt-912
Long-term Liabilities Other 3,843
Long-term Liabilities  (as reported)3,845
Long-term Liabilities  (calculated)3,565
+/- 280
Total Stockholder Equity
Common Stock370,313
Retained Earnings -289,832
Accumulated Other Comprehensive Income 37,773
Total Stockholder Equity (as reported)118,254
Total Stockholder Equity (calculated)118,254
+/-0
Other
Capital Stock370,313
Cash And Equivalents49,573
Cash and Short Term Investments 94,543
Common Stock Shares Outstanding 208,494
Liabilities and Stockholders Equity 151,398
Net Debt -91,561
Net Invested Capital 118,254
Net Working Capital 83,735
Property Plant and Equipment Gross 2,625
Short Long Term Debt Total 1,547



5.3. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-301997-06-301996-06-301995-06-301994-06-301993-06-30
> Total Assets 
5,698
11,313
11,926
9,249
8,693
7,891
6,893
3,682
2,441
844
8,144
6,016
9,064
7,268
5,260
5,163
5,763
4,099
4,687
1,318
2,584
8,631
9,115
9,536
12,678
16,914
30,779
65,205
71,809
147,606
197,063
151,398
151,398197,063147,60671,80965,20530,77916,91412,6789,5369,1158,6312,5841,3184,6874,0995,7635,1635,2607,2689,0646,0168,1448442,4413,6826,8937,8918,6939,24911,92611,3135,698
   > Total Current Assets 
166
5,984
2,019
1,516
3,145
2,962
2,483
795
264
827
2,663
1,350
4,743
3,281
1,626
1,870
2,818
1,494
2,425
1,318
619
1,758
2,515
2,913
6,054
9,833
23,424
34,495
36,319
113,766
165,658
113,034
113,034165,658113,76636,31934,49523,4249,8336,0542,9132,5151,7586191,3182,4251,4942,8181,8701,6263,2814,7431,3502,6638272647952,4832,9623,1451,5162,0195,984166
       Cash And Cash Equivalents 
18
5,558
251
-689
2,035
1,814
2,108
402
29
783
2,618
963
4,346
2,697
1,099
1,620
2,487
793
1,906
1,017
566
1,223
1,957
1,583
4,814
7,822
19,048
30,107
29,487
99,888
153,151
93,108
93,108153,15199,88829,48730,10719,0487,8224,8141,5831,9571,2235661,0171,9067932,4871,6201,0992,6974,3469632,618783294022,1081,8142,035-6892515,55818
       Short-term Investments 
0
0
460
387
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,435
1,43500000000000000000000000000038746000
       Net Receivables 
148
73
193
45
126
666
144
27
61
44
39
385
397
584
527
205
300
522
467
267
54
8
2
1,313
1,220
1,915
4,215
4,194
6,662
12,768
12,105
12,619
12,61912,10512,7686,6624,1944,2151,9151,2201,3132854267467522300205527584397385394461271446661264519373148
       Other Current Assets 
0
0
0
0
0
0
0
102
0
0
45
387
110
542
525
46
31
179
53
301
6
526
556
18
20
96
4,376
194
170
1,110
402
5,872
5,8724021,1101701944,376962018556526630153179314652554211038745001020000000
   > Long-term Assets 
5,532
5,329
9,907
7,733
5,548
4,929
4,410
2,887
2,176
18
5,481
4,666
4,321
3,988
3,634
3,293
2,945
2,605
2,262
1
1,965
6,874
6,600
6,623
6,623
7,081
7,340
30,710
35,490
33,840
31,405
38,364
38,36431,40533,84035,49030,7107,3407,0816,6236,6236,6006,8741,96512,2622,6052,9453,2933,6343,9884,3214,6665,481182,1762,8874,4104,9295,5487,7339,9075,3295,532
       Property Plant Equipment 
28
449
2,522
2,326
2,228
1,916
1,805
1,041
607
17
19
19
15
22
10
10
3
4
2
1
0
0
0
3
3
4
233
156
466
863
683
1,699
1,6996838634661562334330001243101022151919176071,0411,8051,9162,2282,3262,52244928
       Goodwill 
0
0
0
0
0
1
1
1
1
0
4,987
4,648
4,307
0
0
0
0
0
0
0
961
0
0
0
0
0
0
0
0
0
0
0
0000000000096100000004,3074,6484,9870111100000
       Long Term Investments 
0
0
0
0
0
0
450
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
50
81
115
252
218
2,413
2,4132182521158150202000000000000000000450000000
       Intangible Assets 
4,000
3,692
3,385
3,077
2,770
2,463
2,155
1,847
1,568
0
4,987
4,648
4,307
3,965
3,624
3,283
2,942
2,601
2,260
0
1,005
6,874
6,600
6,600
6,600
7,057
7,057
30,458
34,893
32,689
30,486
34,120
34,12030,48632,68934,89330,4587,0577,0576,6006,6006,6006,8741,00502,2602,6012,9423,2833,6243,9654,3074,6484,98701,5681,8472,1552,4632,7703,0773,3853,6924,000
       Long-term Assets Other 
73
566
4,000
2,330
2,770
550
450
-1
0
1
475
0
0
0
0
0
0
0
0
0
-1,965
-6,874
-6,600
-6,623
-6,623
-7,081
-7,340
16
16
35
19
133
13319351616-7,340-7,081-6,623-6,623-6,600-6,874-1,96500000000047510-14505502,7702,3304,00056673
> Total Liabilities 
587
127
1,305
1,127
1,241
1,136
898
903
2,667
52
701
584
412
806
561
493
437
307
480
245
698
1,899
1,383
1,679
1,283
1,439
3,485
5,399
6,791
8,901
7,437
33,143
33,1437,4378,9016,7915,3993,4851,4391,2831,6791,3831,899698245480307437493561806412584701522,6679038981,1361,2411,1271,305127587
   > Total Current Liabilities 
264
127
840
601
1,009
969
755
709
2,667
52
701
584
412
806
561
493
437
307
480
245
167
697
397
694
297
438
2,424
2,899
4,457
7,425
6,084
29,299
29,2996,0847,4254,4572,8992,424438297694397697167245480307437493561806412584701522,6677097559691,009601840127264
       Short-term Debt 
61
34
160
330
332
437
148
143
1,215
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
59
61
106
184
191
912
9121911841066159000000000000000001,2151431484373323301603461
       Short Long Term Debt 
0
0
0
0
0
0
241
286
1,215
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000001,215286241000000
       Accounts payable 
44
49
613
204
138
300
338
208
798
47
422
552
285
689
419
380
269
169
74
117
97
155
98
265
16
289
1,479
1,013
760
4,513
2,341
5,968
5,9682,3414,5137601,0131,47928916265981559711774169269380419689285552422477982083383001382046134944
       Other Current Liabilities 
159
44
67
67
324
232
269
358
654
5
279
33
127
117
142
114
168
138
407
128
70
542
300
428
281
150
944
1,826
3,591
2,727
3,552
22,418
22,4183,5522,7273,5911,82694415028142830054270128407138168114142117127332795654358269232324676744159
   > Long-term Liabilities 
323
0
465
526
232
167
143
194
0
0
0
0
0
0
0
0
0
0
0
0
531
1,202
985
985
985
1,001
1,061
2,499
2,334
1,476
1,353
3,845
3,8451,3531,4762,3342,4991,0611,0019859859851,2025310000000000001941431672325264650323
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
985
985
1,050
8
165
489
362
634
63436248916581,050985985000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
50
52
0
0
0
0
0
0
0
0
0
0
0
0
531
1,202
985
985
985
1,001
997
2,491
2,169
987
991
0
09919872,1692,4919971,0019859859851,2025310000000000005250000000
> Total Stockholder Equity
5,111
11,186
10,621
8,122
7,452
6,755
5,995
2,779
-227
793
7,443
5,432
8,653
6,462
4,700
4,670
5,326
3,791
4,207
1,073
1,886
6,732
7,732
7,857
11,395
15,475
27,295
59,806
65,018
138,705
189,626
118,254
118,254189,626138,70565,01859,80627,29515,47511,3957,8577,7326,7321,8861,0734,2073,7915,3264,6704,7006,4628,6535,4327,443793-2272,7795,9956,7557,4528,12210,62111,1865,111
   Common Stock
4,665
9,115
9,585
10,628
12,162
14,364
24,352
25,556
26,714
28,516
36,751
8,165
13,180
13,180
13,180
14,907
14,907
14,907
14,907
14,907
17,280
24,237
27,652
30,407
36,335
44,286
63,122
92,798
113,107
230,789
314,402
370,313
370,313314,402230,789113,10792,79863,12244,28636,33530,40727,65224,23717,28014,90714,90714,90714,90714,90713,18013,18013,1808,16536,75128,51626,71425,55624,35214,36412,16210,6289,5859,1154,665
   Retained Earnings -289,832-141,436-103,521-65,652-47,310-36,817-29,110-26,143-23,647-20,916-18,476-16,360-14,800-11,667-12,082-10,547-11,197-9,286-6,982-4,527-2,733-29,308-27,963-29,802-25,761-21,341-16,411-11,865-9,683-5,439-3,304-2,429
   Accumulated Other Comprehensive Income 
2,875
5,375
6,475
7,177
7,885
9,532
2,984
2,984
2,861
240
-4
-11
-18
265
806
960
966
966
966
966
966
966
966
1,096
1,202
300
989
14,319
17,563
11,437
16,660
37,773
37,77316,66011,43717,56314,3199893001,2021,096966966966966966966966960806265-18-11-42402,8612,9842,9849,5327,8857,1776,4755,3752,875
   Capital Surplus 00000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000



5.4. Balance Sheets

Currency in AUD. All numbers in thousands.




5.5. Cash Flows

Currency in AUD. All numbers in thousands.




5.6. Income Statements

Currency in AUD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue10,810
Cost of Revenue-5,840
Gross Profit4,9704,970
 
Operating Income (+$)
Gross Profit4,970
Operating Expense-158,688
Operating Income-140,931-153,718
 
Operating Expense (+$)
Research Development86,885
Selling General Administrative59,907
Selling And Marketing Expenses11,702
Operating Expense158,688158,494
 
Net Interest Income (+$)
Interest Income4,516
Interest Expense-478
Other Finance Cost-0
Net Interest Income4,037
 
Pretax Income (+$)
Operating Income-140,931
Net Interest Income4,037
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-154,296-127,566
EBIT - interestExpense = -154,296
-154,296
-149,203
Interest Expense478
Earnings Before Interest and Taxes (EBIT)-153,818-153,818
Earnings Before Interest and Taxes (EBITDA)-147,978
 
After tax Income (+$)
Income Before Tax-154,296
Tax Provision-0
Net Income From Continuing Ops-149,681-154,296
Net Income-149,681
Net Income Applicable To Common Shares-149,681
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses158,688
Total Other Income/Expenses Net-13,365-4,037
 

Technical Analysis of Imugene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Imugene. The general trend of Imugene is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Imugene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Imugene Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Imugene Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.34 < 0.476 < 0.476.

The bearish price targets are: 0.315 > 0.31 > 0.31.

Know someone who trades $IMU? Share this with them.πŸ‘‡

Imugene Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Imugene Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Imugene Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Imugene Ltd. The current macd is 0.00613516.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Imugene price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Imugene. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Imugene price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Imugene Ltd Daily Moving Average Convergence/Divergence (MACD) ChartImugene Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Imugene Ltd. The current adx is 22.11.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Imugene shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Imugene Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Imugene Ltd. The current sar is 0.27714044.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Imugene Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Imugene Ltd. The current rsi is 51.75. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Imugene Ltd Daily Relative Strength Index (RSI) ChartImugene Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Imugene Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Imugene price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Imugene Ltd Daily Stochastic Oscillator ChartImugene Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Imugene Ltd. The current cci is 117.82.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Imugene Ltd Daily Commodity Channel Index (CCI) ChartImugene Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Imugene Ltd. The current cmo is 4.53133479.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Imugene Ltd Daily Chande Momentum Oscillator (CMO) ChartImugene Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Imugene Ltd. The current willr is -57.14285714.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Imugene is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Imugene Ltd Daily Williams %R ChartImugene Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Imugene Ltd.

Imugene Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Imugene Ltd. The current atr is 0.02519106.

Imugene Ltd Daily Average True Range (ATR) ChartImugene Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Imugene Ltd. The current obv is -36,044,498.

Imugene Ltd Daily On-Balance Volume (OBV) ChartImugene Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Imugene Ltd. The current mfi is 59.30.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Imugene Ltd Daily Money Flow Index (MFI) ChartImugene Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Imugene Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-05-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-16CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-24MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-28MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-08-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-08-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-09-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Imugene Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Imugene Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.745
Ma 20Greater thanMa 500.289
Ma 50Greater thanMa 1000.297
Ma 100Greater thanMa 2000.426
OpenGreater thanClose0.340
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Imugene with someone you think should read this too:
  • Are you bullish or bearish on Imugene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Imugene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Imugene Ltd

I send you an email if I find something interesting about Imugene Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Imugene Ltd.

Receive notifications about Imugene Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.